ReviewiScience2026
Reprogramming bone homeostasis: The recoupling-oriented framework of bidirectional regulation strategies for osteoporosis.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current osteoporosis treatments reduce fracture risk by suppressing bone resorption, stimulating bone formation, or combining both effects. Yet these clinical benefits do not show whether formation has resumed at sites where bone was previously resorbed. This Review uses a remodeling recoupling framework to examine this resorption-to-formation transition. We define recoupling as restoration of the sequence from resorption through reversal to osteoblast recruitment and bone formation. This differs from bidirectional regulation, in which osteoblast activity increases and osteoclast activity decreases without evidence that the two responses are linked. We review the cellular communication, signaling pathways, cell-survival mechanisms, and systemic conditions that influence this transition. We also assess candidate targets and treatments according to the strength of clinical, human, animal, and mechanistic evidence. The available evidence is strongest for established therapies and several human-supported pathways, whereas many proposed targets and delivery approaches remain preclinical. This framework may help guide treatment sequencing, patient selection, bone-targeted delivery, and the development of measures that determine whether formation follows resorption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.